Skip to main content
SpringerLink
Log in
Book cover

Systemic Corticosteroids for Inflammatory Disorders in Pediatrics pp 95–103Cite as

Corticosteroids in Pediatric-Onset SLE and Other Connective Tissue Diseases

  • Chapter

  • 783 Accesses

Abstract

Glucocorticoids (GCs) are potent anti-inflammatory drugs and have been widely used in many inflammatory diseases including connective tissue diseases (CTDs) in children. Although steroids are effective in controlling severe diseases such as juvenile systemic lupus erythematosus (SLE), it has become clear that they are associated with numerous side effects; it is now known that steroids should be used in GC-sparing regimens. In this chapter, we underscore the major impact of these drugs in disease control during the treatment of CTDs and we present new long-term therapeutic strategies aimed at reducing GC exposure. Steroids account for an important burden of the disease, especially in SLE where the cumulative steroid dose is considered damaging. SLE is the paradigm of autoimmune diseases; therefore, we review the impact of steroids in such conditions with a focus on juvenile SLE.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Belot A, Cimaz R (2012) Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediatr Rheumatol Online J 10:21

    Article  PubMed Central  PubMed  Google Scholar 

  2. Watson L et al (2012) Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheum 64:2356–2365

    Article  PubMed  Google Scholar 

  3. Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808

    Article  CAS  PubMed  Google Scholar 

  4. Marks SD, Sebire NJ, Pilkington C, Tullus K (2007) Clinicopathological correlations of paediatric lupus nephritis. Pediatr Nephrol 22:77–83

    Article  PubMed  Google Scholar 

  5. Mina R et al (2012) Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res 64:375–383

    Article  Google Scholar 

  6. Appel GB et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Houssiau FA et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131

    Article  CAS  PubMed  Google Scholar 

  8. Guiducci C et al (2010) TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465:937–941

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Aggarwal A, Srivastava P (2015) Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis 18:182–191 n/a–n/a. doi:10.1111/1756-185X.12419

  10. Dooley MA et al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365:1886–1895

    Article  CAS  PubMed  Google Scholar 

  11. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46:436–444

    Article  PubMed  Google Scholar 

  12. Gutiérrez-Suárez R et al (2006) A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 54:2989–2996

    Article  PubMed  Google Scholar 

  13. Rygg M et al (2012) A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis 71:511–517

    Article  PubMed  Google Scholar 

  14. Stagi S et al (2014) Comparison of bone mass and quality determinants in adolescents and young adults with juvenile systemic lupus erythematosus (JSLE) and juvenile idiopathic arthritis (JIA). Lupus. doi:10.1177/0961203314543916

    Google Scholar 

  15. Alsufyani KA et al (2005) Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 32:729–733

    CAS  PubMed  Google Scholar 

  16. Lilleby V et al (2005) Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum 52:2051–2059

    Article  PubMed  Google Scholar 

  17. Lilleby V (2007) Review: bone status in juvenile systemic lupus erythematosus. Lupus 16:580–586

    Article  CAS  PubMed  Google Scholar 

  18. Rudge S et al (2005) Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 44:813–818

    Article  CAS  Google Scholar 

  19. Petri M, Lakatta C, Magder L, Goldman D (1994) Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 96:254–259

    Article  CAS  PubMed  Google Scholar 

  20. Ardoin SP et al (2014) Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis 73:557–566

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Vachvanichsanong P, Dissaneewate P, McNeil E (2011) Twenty-two years’ experience with childhood-onset SLE in a developing country: are outcomes similar to developed countries? Arch Dis Child 96:44–49

    Article  PubMed  Google Scholar 

  22. Cimaz R (2012) Pediatric rheumatic disease: treating lupus nephritis in children–is there a gold standard? Nat Rev Rheumatol 8:192–193

    Article  CAS  PubMed  Google Scholar 

  23. Ranchin B, Fargue S (2007) New treatment strategies for proliferative lupus nephritis: keep children in mind! Lupus 16:684–691

    Article  CAS  PubMed  Google Scholar 

  24. Bao H et al (2008) Successful treatment of class V + IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19:2001–2010

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Lanata CM, Mahmood T, Fine DM, Petri M (2010) Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus 19:935–940

    Article  CAS  PubMed  Google Scholar 

  26. Cortés-Hernández J, Torres-Salido MT, Medrano AS, Tarrés MV, Ordi-Ros J (2010) Long-term outcomes–mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 25:3939–3948

    Article  PubMed  Google Scholar 

  27. Tanaka H et al (2014) Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. Lupus 23:813–818

    Article  CAS  PubMed  Google Scholar 

  28. Rovin BH et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215–1226

    Article  CAS  PubMed  Google Scholar 

  29. Condon MB et al (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72:1280–1286

    Article  CAS  PubMed  Google Scholar 

  30. Weidenbusch M, Römmele C, Schröttle A, Anders H-J (2013) Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 28:106–111

    Article  CAS  PubMed  Google Scholar 

  31. Furie R et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930

    Article  CAS  PubMed  Google Scholar 

  32. Hui-Yuen JS et al (2014) A23: favorable response to belimumab in childhood-onset systemic lupus erythematosus. Arthritis Rheum 66 Suppl 11:S37, Hoboken

    Article  Google Scholar 

  33. Feldman BM, Rider LG, Reed AM, Pachman LM (2008) Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371:2201–2212

    Article  PubMed  Google Scholar 

  34. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT (1983) Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103:882–888

    Article  CAS  PubMed  Google Scholar 

  35. Klein-Gitelman MS, Waters T, Pachman LM (2000) The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 13:360–368

    Article  CAS  PubMed  Google Scholar 

  36. Rouster-Stevens KA et al (2007) RANKL: osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum 56:977–983

    Article  CAS  PubMed  Google Scholar 

  37. Michels H (1997) Course of mixed connective tissue disease in children. Ann Med 29:359–364

    Article  CAS  PubMed  Google Scholar 

  38. Mier RJ et al (2005) Pediatric-onset mixed connective tissue disease. Rheum Dis Clin North Am 31:483–496, vii

    Article  PubMed  Google Scholar 

  39. Johnson W, Jacobe H (2012) Morphea in adults and children cohort II: patients with morphea experience delay in diagnosis and large variation in treatment. J Am Acad Dermatol 67:881–889

    Article  PubMed  Google Scholar 

  40. Li SC et al (2012) Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res 64:1175–1185

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Rheumatology and Nephrology Department, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Université de Lyon, INSERM U1111, Lyon, France

    Alexandre Belot MD, PhD

Authors
  1. Alexandre Belot MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandre Belot MD, PhD .

Editor information

Editors and Affiliations

  1. AOU Meyer Pediatric Rheumatology, Firenze, Italy

    Rolando Cimaz

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Belot, A. (2015). Corticosteroids in Pediatric-Onset SLE and Other Connective Tissue Diseases. In: Cimaz, R. (eds) Systemic Corticosteroids for Inflammatory Disorders in Pediatrics. Adis, Cham. https://doi.org/10.1007/978-3-319-16056-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16056-6_8

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-16055-9

  • Online ISBN: 978-3-319-16056-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation